O. A. Volkova
Research Subjects
Research Interests
O. A. Volkova has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Vitaliy Vladimirovich Omelyanovskiy
Center for Healthcare Quality Assessment and Control; Russian Medical Academy of Continuing Professional Education
8 shared publications - D. V. Fedyaev
Center for Healthcare Quality Assessment and Control; Russian Medical Academy of Continuing Professional Education; Financial Research Institute
7 shared publications - Inna Alexandrovna Zheleznyakova
Center for Expertise and Quality Control of Medical Care
7 shared publications - O. S. Plakhotnik
Center for Expertise and Quality Control of Medical Care
6 shared publications - A. V. Zuev
Center for Expertise and Quality Control of Medical Care
5 shared publications - G. V. Trifonova
Center for Healthcare Quality Assessment and Control
5 shared publications
Latest Publications
- 22 January 2026
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 18 (4) , 513-520
From variability to uniformity: standardizing tariff agreements as a tool for improving the efficiency of the compulsory health insurance system
Background. At present, the compulsory health insurance (CHI) system in the Russian Federation is lacking a standardized format for tariff agreements. This leads to significant variability in the structure of documents and, consequently, to errors, low transparency of tariff policy, and financial control difficulties. Objective: To develop a unified form of tariff agreement in the Russian CHI system. Material and methods. The research methodology was based on an integrated analysis of the regulatory framework and regional tariff agreements, followed by testing of the developed form in pilot Russian regions. Results. A unified form of tariff agreement has been developed. This standardized form minimizes the administrative burden on participants in the CHI system, ensures transparency in tariff formation, enables comparative analysis of regional indicators, and optimizes the process of document approval by the Federal CHI Fund. Conclusion. T he introduction of the standardized form for tariff agreements and the digitization of their processing will significantly improve the efficiency of tariff policy management in the CHI system of Russia.
- 22 January 2026
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 18 (4) , 513-520
From variability to uniformity: standardizing tariff agreements as a tool for improving the efficiency of the compulsory health insurance system
Background. At present, the compulsory health insurance (CHI) system in the Russian Federation is lacking a standardized format for tariff agreements. This leads to significant variability in the structure of documents and, consequently, to errors, low transparency of tariff policy, and financial control difficulties. Objective: To develop a unified form of tariff agreement in the Russian CHI system. Material and methods. The research methodology was based on an integrated analysis of the regulatory framework and regional tariff agreements, followed by testing of the developed form in pilot Russian regions. Results. A unified form of tariff agreement has been developed. This standardized form minimizes the administrative burden on participants in the CHI system, ensures transparency in tariff formation, enables comparative analysis of regional indicators, and optimizes the process of document approval by the Federal CHI Fund. Conclusion. T he introduction of the standardized form for tariff agreements and the digitization of their processing will significantly improve the efficiency of tariff policy management in the CHI system of Russia.
- 1 January 2026
- Published by FSBI Scientific and Research Financial Institute in Financial Journal
- Vol. 18 (5)
Economic Evaluation of Medical Care Procedures: Methodology and Practical Application
The article is devoted to the development of a methodological approach for the comprehensive eco nomic assessment of Procedures for Rendering Medical Care (PRMC) and the calculation of additional funding requirements upon their updating. The proposed approach is based on the principles of system analysis and elementbyelement decomposition, which make it possible to move from lineitem costing to integrated financial modeling. The essence of the approach lies in considering the integral cost of PRMC implementation as a dynamic model, where changes in one structural block trigger cascading financial consequences in others. The practical implementation of the methodology, including comparative cost assessment of current and draft documents and calculation of additional funding needs, was carried out using data from public procurement of medical equipment and official Rosstat statistics on wages. The results of the analysis confirm that the proposed methodology allows not only to assess total costs but also to identify specific reasons for cost increases, quantify the scale of such increases due to regulatory updates, and substantiate tariff changes within the public healthcare financing system. Thus, the presented methodology can serve as a foundation for more evidencebased budget planning and financially responsible management decisions when updating industryspecific regulatory acts, which determines its practical significance for economists, analysts, heads of medical organizations, and developers of regulatory documents.
- 1 January 2026
- Published by FSBI Scientific and Research Financial Institute in Financial Journal
- Vol. 18 (5)
Economic Evaluation of Medical Care Procedures: Methodology and Practical Application
The article is devoted to the development of a methodological approach for the comprehensive eco nomic assessment of Procedures for Rendering Medical Care (PRMC) and the calculation of additional funding requirements upon their updating. The proposed approach is based on the principles of system analysis and elementbyelement decomposition, which make it possible to move from lineitem costing to integrated financial modeling. The essence of the approach lies in considering the integral cost of PRMC implementation as a dynamic model, where changes in one structural block trigger cascading financial consequences in others. The practical implementation of the methodology, including comparative cost assessment of current and draft documents and calculation of additional funding needs, was carried out using data from public procurement of medical equipment and official Rosstat statistics on wages. The results of the analysis confirm that the proposed methodology allows not only to assess total costs but also to identify specific reasons for cost increases, quantify the scale of such increases due to regulatory updates, and substantiate tariff changes within the public healthcare financing system. Thus, the presented methodology can serve as a foundation for more evidencebased budget planning and financially responsible management decisions when updating industryspecific regulatory acts, which determines its practical significance for economists, analysts, heads of medical organizations, and developers of regulatory documents.
- Open Access
- 4 August 2024
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 17 (2) , 137-151
Methodology of forming a model of diagnosis-related groups for cases of medical care using surgery performed by laparoscopic access
Background. A wide range of endosurgical treatment methods in various medical care profiles and the need for uniformity of calculations required developing a unified approach to the formation of diagnosis-related groups (DRGs) for cases of surgical medical care provided by laparoscopic access.Objective: to develop a methodology for the formation of a DRG model for cases of medical care using surgery performed by laparoscopic access in the context of the following medical care profiles: “coloproctology”, “urology”, “surgery (abdominal)”, “obstetrics and gynecology”, “pediatric urology-andrology”, “pediatric surgery”.Material and methods. The methodology for the formation of DRGs to pay for cases of medical care using surgery with laparoscopic access included the implementation of several stages: analysis of scientific and methodological documents, analysis of regulatory legal documents on the research topic, standardized expert survey of federal and regional medical centers (carried out in August 2023), formation of DRGs in the context of each profile, and calculation of cost-intensity coefficients.Results. Due to significant increase in the cost-intensity coefficient in nine newly formed DRGs to pay for cases of medical care provided by surgery with laparoscopic access, financial support of this type of surgical medical care almost doubled. The formed DRGs with appropriate cost-intensity coefficients were included in the Program on State Guarantees to Deliver Free Medical Care to the Citizens for 2024 and for the planning period of 2025 and 2026.Conclusion. The methodology of forming DRGs to pay for cases of medical care using surgery performed by laparoscopic access with a unified methodology for calculating costs for medical care provided an integrated approach to the process of forming DRGs for cases of surgical medical care, and unification of calculations for different medical care profiles.
- 4 August 2024
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 17 (2) , 137-151
Open AccessMethodology of forming a model of diagnosis-related groups for cases of medical care using surgery performed by laparoscopic access
Background. A wide range of endosurgical treatment methods in various medical care profiles and the need for uniformity of calculations required developing a unified approach to the formation of diagnosis-related groups (DRGs) for cases of surgical medical care provided by laparoscopic access.Objective: to develop a methodology for the formation of a DRG model for cases of medical care using surgery performed by laparoscopic access in the context of the following medical care profiles: “coloproctology”, “urology”, “surgery (abdominal)”, “obstetrics and gynecology”, “pediatric urology-andrology”, “pediatric surgery”.Material and methods. The methodology for the formation of DRGs to pay for cases of medical care using surgery with laparoscopic access included the implementation of several stages: analysis of scientific and methodological documents, analysis of regulatory legal documents on the research topic, standardized expert survey of federal and regional medical centers (carried out in August 2023), formation of DRGs in the context of each profile, and calculation of cost-intensity coefficients.Results. Due to significant increase in the cost-intensity coefficient in nine newly formed DRGs to pay for cases of medical care provided by surgery with laparoscopic access, financial support of this type of surgical medical care almost doubled. The formed DRGs with appropriate cost-intensity coefficients were included in the Program on State Guarantees to Deliver Free Medical Care to the Citizens for 2024 and for the planning period of 2025 and 2026.Conclusion. The methodology of forming DRGs to pay for cases of medical care using surgery performed by laparoscopic access with a unified methodology for calculating costs for medical care provided an integrated approach to the process of forming DRGs for cases of surgical medical care, and unification of calculations for different medical care profiles.
- 23 April 2024
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 46 (3)
Cost of supportive cancer care in the Russian Federation. Part 1
Objective. Modeling of annual cost of supportive therapy for malignant neoplasms in accordance with the guidelines of the All-Russian public organization “Russian Society of Clinical Oncology” (RUSSCO). Material and methods. The main material for modelling the cost of treatment were drug regimens presented in the RUSSCO guidelines for the following complications: chronic viral hepatitis B, hormone-mediated side effects, bone tissue pathology, immune-mediated side effects, mucositis, infusion reactions, thromboembolic complications, chronic pain syndrome, anorexia-cachexia syndrome, as well as enzyme replacement therapy for pancreatic cancer and nutritional support. To calculate population receiving anticancer drug therapy, we used data on medical billing registry database (2022). This database contains information on the number of completed cases of anticancer drug therapy and the number of appropriate patients. During the modeling, we hypothetically divided financing depending on the profiles of medical care and sources of funding. Results. The most expensive cases (87.2% of overall requirement) are treatment of bone lesions (5.532.288.615.94 rubles), thromboembolic complications (5.973.880.025.31 rubles), chronic pain syndrome (6.309.163.258.86 rubles) and nutritional support (7.009.301.585.00 rubles). Approximately 75% of the estimated funding is for «oncology» profile, i.e. treatment of complications will take place during chemotherapy period. In the current model, 47% of funding goes from the state programs of free drug supply, 28% from compulsory medical insurance to cover stay at the day and 24-hour hospitals, 23% from personal patients’ expenses. Conclusion. Modeling of supportive cancer therapy cost can underlie changes in medical care payment system.
- 23 April 2024
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 46 (3)
Cost of supportive cancer care in the Russian Federation. Part 1
Objective. Modeling of annual cost of supportive therapy for malignant neoplasms in accordance with the guidelines of the All-Russian public organization “Russian Society of Clinical Oncology” (RUSSCO). Material and methods. The main material for modelling the cost of treatment were drug regimens presented in the RUSSCO guidelines for the following complications: chronic viral hepatitis B, hormone-mediated side effects, bone tissue pathology, immune-mediated side effects, mucositis, infusion reactions, thromboembolic complications, chronic pain syndrome, anorexia-cachexia syndrome, as well as enzyme replacement therapy for pancreatic cancer and nutritional support. To calculate population receiving anticancer drug therapy, we used data on medical billing registry database (2022). This database contains information on the number of completed cases of anticancer drug therapy and the number of appropriate patients. During the modeling, we hypothetically divided financing depending on the profiles of medical care and sources of funding. Results. The most expensive cases (87.2% of overall requirement) are treatment of bone lesions (5.532.288.615.94 rubles), thromboembolic complications (5.973.880.025.31 rubles), chronic pain syndrome (6.309.163.258.86 rubles) and nutritional support (7.009.301.585.00 rubles). Approximately 75% of the estimated funding is for «oncology» profile, i.e. treatment of complications will take place during chemotherapy period. In the current model, 47% of funding goes from the state programs of free drug supply, 28% from compulsory medical insurance to cover stay at the day and 24-hour hospitals, 23% from personal patients’ expenses. Conclusion. Modeling of supportive cancer therapy cost can underlie changes in medical care payment system.
- 23 April 2024
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 46 (2)
Changes in diagnosis-related group payment model in the Russian Federation in 2024
We actualized the content and/or weight coefficients of Russian diagnosis-related groups (DRG) for inpatient and day medical care payment. Costs of medicines were calculated using actual purchase prices. Thus the weight coefficients were recalculated for several DRG including admissions for antineoplastic therapy, chronic hepatitits C treatment and treatment with the use of genetically engineered biological drugs and selective immunosupressors. Three levels of patient treatment complexity coefficients were introduced to reimburse the cost of supportive therapy in oncology. Weight coefficients for payment for radionuclide therapy were recalculated. We actualized drug therapy regimens lists covered by DRG payment. It was made for antineoplastic therapy regimens and regimens of genetically engineered drugs and selective immunosuppressors. Charges for inpatient minimally invasive operations were increased via identifying 9 new groups. Payment approaches for immunization against respiratory syncytial infection were improved. The updated grouping algorithm of cases in oncology is described.
- 23 April 2024
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 46 (2)
Changes in diagnosis-related group payment model in the Russian Federation in 2024
We actualized the content and/or weight coefficients of Russian diagnosis-related groups (DRG) for inpatient and day medical care payment. Costs of medicines were calculated using actual purchase prices. Thus the weight coefficients were recalculated for several DRG including admissions for antineoplastic therapy, chronic hepatitits C treatment and treatment with the use of genetically engineered biological drugs and selective immunosupressors. Three levels of patient treatment complexity coefficients were introduced to reimburse the cost of supportive therapy in oncology. Weight coefficients for payment for radionuclide therapy were recalculated. We actualized drug therapy regimens lists covered by DRG payment. It was made for antineoplastic therapy regimens and regimens of genetically engineered drugs and selective immunosuppressors. Charges for inpatient minimally invasive operations were increased via identifying 9 new groups. Payment approaches for immunization against respiratory syncytial infection were improved. The updated grouping algorithm of cases in oncology is described.
- Open Access
- 20 July 2023
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 16 (2) , 266-282
Methodological approach to the formation of the list of high-tech medical care types
Background. The implementation of individual methods of high-tech medical care (HTMC) with methods of specialized medical care within the framework of a phased transition to payment methods by diagnostic-related groups (DRGs), on the one hand, significantly expanded the availability of HTMC methods for the population. Still, it created a situation with duplication of individual treatment methods in the list of HTMC types and DRGs. Amendments to the Order of the Ministry of Health of the Russian Federation (MH RF) of August 1, 2017 No. 484n, regulating the revision of HTMC types list in terms of excluding treatment methods and (or) HTMC types in case of their duplication in the context of HTMC groups and/or DRGs, marked the beginning of large-scale work in this area and required methodological ensuring the processes of forming HTMC types list, including in terms of its revision.Objective: development of a methodological approach to the formation of HTMC types list (using the example of the list for 2023). Material and methods. An analysis of legal documents regulating the HTMC availability in the Russian Federation was carried out, including the list of medical services approved by the Order of the MH RF of October 13, 2017 No. 804n, clinical recommendations for certain nosological entities, the International Classification of Diseases (10th revision), methodological recommendations on ways to pay for medical care at the expense of the compulsory health insurance (CHI) and appendices to them (decoders of DRGs for payment of medical care provided in inpatient and daytime hospital conditions), posted on the official website of the Federal CHI Fund. The frequency of the use of certain HTMC methods and DRGs was analyzed on the basis of impersonalized information from the database of registers of bills for specialized medical care, including HTMC for 2021–2022.Results. A methodological approach to the revision of HTMC types list was developed. It included its primary analysis, expert discussion of the obtained results, consideration by the Interdepartmental Council of the MH RF of proposals agreed with experts on each HTMC method submitted for discussion, followed by a decision on the appropriateness of the proposed changes, and recalculation of the standard of financial costs for HTMC and/or basic tariff for DRGs.Conclusion. The proposed methodological approach makes it possible to unify the process of revising the HTMC types list, including the exclusion of duplicate treatment methods and/or HTMC types in the sections of HTMC list types and/or in DRGs, as well as treatment methods missing in clinical recommendations, etc. in order to bring the HTMC types list in accordance with legal documents regulating the provision of medical care in the Russian Federation.
- 20 July 2023
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 16 (2) , 266-282
Open AccessMethodological approach to the formation of the list of high-tech medical care types
Background. The implementation of individual methods of high-tech medical care (HTMC) with methods of specialized medical care within the framework of a phased transition to payment methods by diagnostic-related groups (DRGs), on the one hand, significantly expanded the availability of HTMC methods for the population. Still, it created a situation with duplication of individual treatment methods in the list of HTMC types and DRGs. Amendments to the Order of the Ministry of Health of the Russian Federation (MH RF) of August 1, 2017 No. 484n, regulating the revision of HTMC types list in terms of excluding treatment methods and (or) HTMC types in case of their duplication in the context of HTMC groups and/or DRGs, marked the beginning of large-scale work in this area and required methodological ensuring the processes of forming HTMC types list, including in terms of its revision.Objective: development of a methodological approach to the formation of HTMC types list (using the example of the list for 2023). Material and methods. An analysis of legal documents regulating the HTMC availability in the Russian Federation was carried out, including the list of medical services approved by the Order of the MH RF of October 13, 2017 No. 804n, clinical recommendations for certain nosological entities, the International Classification of Diseases (10th revision), methodological recommendations on ways to pay for medical care at the expense of the compulsory health insurance (CHI) and appendices to them (decoders of DRGs for payment of medical care provided in inpatient and daytime hospital conditions), posted on the official website of the Federal CHI Fund. The frequency of the use of certain HTMC methods and DRGs was analyzed on the basis of impersonalized information from the database of registers of bills for specialized medical care, including HTMC for 2021–2022.Results. A methodological approach to the revision of HTMC types list was developed. It included its primary analysis, expert discussion of the obtained results, consideration by the Interdepartmental Council of the MH RF of proposals agreed with experts on each HTMC method submitted for discussion, followed by a decision on the appropriateness of the proposed changes, and recalculation of the standard of financial costs for HTMC and/or basic tariff for DRGs.Conclusion. The proposed methodological approach makes it possible to unify the process of revising the HTMC types list, including the exclusion of duplicate treatment methods and/or HTMC types in the sections of HTMC list types and/or in DRGs, as well as treatment methods missing in clinical recommendations, etc. in order to bring the HTMC types list in accordance with legal documents regulating the provision of medical care in the Russian Federation.
- Open Access
- 19 July 2023
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 16 (2) , 196-208
Improving the model of payment for medical care for chronic viral hepatitis C in the framework of the implementation of the Program of State Guarantees of Free Provision of Medical Care to Citizens for 2023 and for the planned period of 2024–2025
Background. In 2021, new clinical guidelines for the treatment of chronic hepatitis C virus (HCV) in adults were published that did not contain interferon drug therapy regimens. Current therapy of chronic HCV is based on modern drugs of direct-acting antivirals (DAA). In this regard, the model of diagnosis-related groups (DRG) with the use of interferon-containing drugs as etiotropic therapy, which has been in effect until now, has lost its relevance and cannot be used to pay for cases of medical care for chronic HCV within the framework of the Program of State Guarantees of Free Medical Care to Citizens for 2023 and for the planning period of 2024–2025 (PSG). Objective: to improve the DRG model to pay for medical care for chronic HCV in a day hospital based on current clinical recommendations.Material and methods. Regulatory legal documents on the subject of the study, proposals and expert opinions of specialists, as well as feedback from public organizations, including patients, regarding the payment of medical care for chronic HCV, sent as part of a public discussion of the draft PSG, were studied. For the calculations were used: the current version of the clinical recommendations "Chronic viral hepatitis C"; impersonal personalized information of the database of registers of bills for payment for medical care for 2020–2021; the state register of manufacturers' maximum selling prices for medicines included in the list of vital and essential drugs.Results. A DRG model was developed to pay for medical care during drug therapy of chronic HCV, including for children. When calculating the model, the cost of medicines, patient days and the principles of accounting for the duration of hospitalization were updated.Conclusion. The developed DRG model to pay for medical care for chronic HCV in a day hospital with the use of drug therapy regimens with DAA recommended by clinical guidelines, including for children with HCV, contributes to improving the effectiveness of the system of payment for medical care provided as part of the implementation of the PSG and accessibility of medical care for this contingent of patients.
- 19 July 2023
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 16 (2) , 196-208
Open AccessImproving the model of payment for medical care for chronic viral hepatitis C in the framework of the implementation of the Program of State Guarantees of Free Provision of Medical Care to Citizens for 2023 and for the planned period of 2024–2025
Background. In 2021, new clinical guidelines for the treatment of chronic hepatitis C virus (HCV) in adults were published that did not contain interferon drug therapy regimens. Current therapy of chronic HCV is based on modern drugs of direct-acting antivirals (DAA). In this regard, the model of diagnosis-related groups (DRG) with the use of interferon-containing drugs as etiotropic therapy, which has been in effect until now, has lost its relevance and cannot be used to pay for cases of medical care for chronic HCV within the framework of the Program of State Guarantees of Free Medical Care to Citizens for 2023 and for the planning period of 2024–2025 (PSG). Objective: to improve the DRG model to pay for medical care for chronic HCV in a day hospital based on current clinical recommendations.Material and methods. Regulatory legal documents on the subject of the study, proposals and expert opinions of specialists, as well as feedback from public organizations, including patients, regarding the payment of medical care for chronic HCV, sent as part of a public discussion of the draft PSG, were studied. For the calculations were used: the current version of the clinical recommendations "Chronic viral hepatitis C"; impersonal personalized information of the database of registers of bills for payment for medical care for 2020–2021; the state register of manufacturers' maximum selling prices for medicines included in the list of vital and essential drugs.Results. A DRG model was developed to pay for medical care during drug therapy of chronic HCV, including for children. When calculating the model, the cost of medicines, patient days and the principles of accounting for the duration of hospitalization were updated.Conclusion. The developed DRG model to pay for medical care for chronic HCV in a day hospital with the use of drug therapy regimens with DAA recommended by clinical guidelines, including for children with HCV, contributes to improving the effectiveness of the system of payment for medical care provided as part of the implementation of the PSG and accessibility of medical care for this contingent of patients.
- 21 June 2023
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 45 (2)
Improving the model of payment for medical care for infertility using assisted reproductive technologies in the program of state guarantees of free medical care to citizens for 2023 and 2024—2025
Утверждение Приказом Минздрава России от 31.07.20 №803н1 порядка использования вспомогательных репродуктивных технологий (ВРТ) и обновление в 2021 г. клинических рекомендации «Женское бесплодие» потребовало пересмотра существующих клинико-статистических групп (КСГ) для оплаты экстракорпорального оплодотворения (ЭКО). В кооперации с экспертами ведущих центров репродуктологии на основании клинических рекомендаций «Женское бесплодие» актуализирован перечень медицинских услуг, оказываемых на разных этапах цикла ЭКО. Произведен пересчет стоимости расходных материалов, лекарственных препаратов, заработной платы медицинских работников, принимающих непосредственное участие в оказании медицинских услуг, накладных расходов медицинских организаций. Источниками информации для расчета затрат служили: обезличенные персонифицированные сведения из базы реестров счетов на оплату за оказание медицинской помощи в 2020—2021 гг., государственный реестр предельных отпускных цен производителей на лекарственные препараты, включенные в Перечень жизненно необходимых и важнейших лекарственных препаратов, данные медицинских организаций о закупках в единой информационной системе в сфере закупок. Пересчитанные коэффициенты относительной затратоемкости КСГ на всех уровнях базовой программы ЭКО увеличились по сравнению с прошлым годом, в структуре тарифа на каждую КСГ выделена доля заработной платы и прочих расходов медицинских организаций.
- 21 June 2023
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 45 (2)
Improving the model of payment for medical care for infertility using assisted reproductive technologies in the program of state guarantees of free medical care to citizens for 2023 and 2024—2025
Утверждение Приказом Минздрава России от 31.07.20 №803н1 порядка использования вспомогательных репродуктивных технологий (ВРТ) и обновление в 2021 г. клинических рекомендации «Женское бесплодие» потребовало пересмотра существующих клинико-статистических групп (КСГ) для оплаты экстракорпорального оплодотворения (ЭКО). В кооперации с экспертами ведущих центров репродуктологии на основании клинических рекомендаций «Женское бесплодие» актуализирован перечень медицинских услуг, оказываемых на разных этапах цикла ЭКО. Произведен пересчет стоимости расходных материалов, лекарственных препаратов, заработной платы медицинских работников, принимающих непосредственное участие в оказании медицинских услуг, накладных расходов медицинских организаций. Источниками информации для расчета затрат служили: обезличенные персонифицированные сведения из базы реестров счетов на оплату за оказание медицинской помощи в 2020—2021 гг., государственный реестр предельных отпускных цен производителей на лекарственные препараты, включенные в Перечень жизненно необходимых и важнейших лекарственных препаратов, данные медицинских организаций о закупках в единой информационной системе в сфере закупок. Пересчитанные коэффициенты относительной затратоемкости КСГ на всех уровнях базовой программы ЭКО увеличились по сравнению с прошлым годом, в структуре тарифа на каждую КСГ выделена доля заработной платы и прочих расходов медицинских организаций.
- 21 June 2023
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 45 (2)
Main changes in payment model for diagnosis-related groups in the Russian Federation in 2023
The content and/or weight coefficients of diagnosis-related groups for payment for medical care in a inpatient and day hospital have been updated for 2023. A significant part of changes is justified by exclusion of duplication of treatment methods in the model of diagnosis-related group and list of types of high-tech medical care. The content of oncological diagnosis-related groups including those intended to pay for therapeutic and surgical treatment of malignancies has been updated. It became possible to pay for immune phenotyping in oncohematological diseases. There are changes in formation of diagnosis-related groups to pay for treatment with genetically engineered biological drugs and selective immune suppressants. In particular, the number of groups formed according to a new classification criterion (therapy regimen and age) has been increased. New diagnosis-related group was created in order to pay for initiation of therapy in an inpatient and day hospital. Payment for immunization against respiratory syncytial viral infection has been revised, i.e. diagnosis-related groups were differentiated into 2 levels of costs depending on the age of the child. The specialists updated the content and cost of groups to pay for antimicrobial therapy of multidrug-resistant infections in addition to the main diagnosis-related group applied in accordance with the main reason for hospitalization. The approaches to payment for medical rehabilitation, in vitro fertilization, sling surgeries for urinary incontinence, chronic viral hepatitis C, phacoemulsification with intraocular lens implantation and radioiodine therapy for thyrotoxicosis have been improved. Weight coefficients of the diagnosis-related groups for payment of the treatment of a new coronavirus infection (COVID-19) were recalculated. Conditions for using complexity coefficients in the treatment of patients including drug therapy for cancer in adults have been expanded.
- 21 June 2023
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 45 (2)
Main changes in payment model for diagnosis-related groups in the Russian Federation in 2023
The content and/or weight coefficients of diagnosis-related groups for payment for medical care in a inpatient and day hospital have been updated for 2023. A significant part of changes is justified by exclusion of duplication of treatment methods in the model of diagnosis-related group and list of types of high-tech medical care. The content of oncological diagnosis-related groups including those intended to pay for therapeutic and surgical treatment of malignancies has been updated. It became possible to pay for immune phenotyping in oncohematological diseases. There are changes in formation of diagnosis-related groups to pay for treatment with genetically engineered biological drugs and selective immune suppressants. In particular, the number of groups formed according to a new classification criterion (therapy regimen and age) has been increased. New diagnosis-related group was created in order to pay for initiation of therapy in an inpatient and day hospital. Payment for immunization against respiratory syncytial viral infection has been revised, i.e. diagnosis-related groups were differentiated into 2 levels of costs depending on the age of the child. The specialists updated the content and cost of groups to pay for antimicrobial therapy of multidrug-resistant infections in addition to the main diagnosis-related group applied in accordance with the main reason for hospitalization. The approaches to payment for medical rehabilitation, in vitro fertilization, sling surgeries for urinary incontinence, chronic viral hepatitis C, phacoemulsification with intraocular lens implantation and radioiodine therapy for thyrotoxicosis have been improved. Weight coefficients of the diagnosis-related groups for payment of the treatment of a new coronavirus infection (COVID-19) were recalculated. Conditions for using complexity coefficients in the treatment of patients including drug therapy for cancer in adults have been expanded.
- Open Access
- 15 January 2022
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 14 (4) , 549-562
Experience of using telemedicine technologies in healthcare systems of foreign countries and the Russian Federation: systematic review
Background. Today, the development and widespread use of digital technologies in medicine is considered as one of the most promising mechanisms for optimizing costs and improving the efficiency of healthcare and the quality of life of the aging society.Objective: to study the experience of using telemedicine technologies for providing medical care in the health systems of different countries, including the Russian Federation.Material and methods. To obtain the necessary information, an overview of the most relevant studies published in Medscape, PubMed/ MEDLINE, ScienceDirect, Scopus, eLibrary, CyberLeninka databases, World Health Organization repository and open sources from Google and Yandex search, as well as relevant regulatory documents was carried out.Results. The experience of using telemedicine technologies for medical care in healthcare systems of different countries, including Russia, presented in the article, demonstrates both the advantages of these technologies, and the limitations for their use in healthcare.Conclusion. Despite all the undisputed advantages of telemedicine technologies, their development should not become an end in itself. The expediency of their use in each specific case of providing medical care and exclusively as another, additional tool to improve the quality and accessibility of medical care should be considered.
- 15 January 2022
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 14 (4) , 549-562
Open AccessExperience of using telemedicine technologies in healthcare systems of foreign countries and the Russian Federation: systematic review
Background. Today, the development and widespread use of digital technologies in medicine is considered as one of the most promising mechanisms for optimizing costs and improving the efficiency of healthcare and the quality of life of the aging society.Objective: to study the experience of using telemedicine technologies for providing medical care in the health systems of different countries, including the Russian Federation.Material and methods. To obtain the necessary information, an overview of the most relevant studies published in Medscape, PubMed/ MEDLINE, ScienceDirect, Scopus, eLibrary, CyberLeninka databases, World Health Organization repository and open sources from Google and Yandex search, as well as relevant regulatory documents was carried out.Results. The experience of using telemedicine technologies for medical care in healthcare systems of different countries, including Russia, presented in the article, demonstrates both the advantages of these technologies, and the limitations for their use in healthcare.Conclusion. Despite all the undisputed advantages of telemedicine technologies, their development should not become an end in itself. The expediency of their use in each specific case of providing medical care and exclusively as another, additional tool to improve the quality and accessibility of medical care should be considered.